Biotech is the most valuable asset class, yet it remains inherently illiquid. The core problem is simple: you cannot trade what you cannot measure.

At floatz, we are building the pricing infrastructure to make biotech a liquid asset class. We turn complex science into financial signals by providing the standardized ratings that make biotech tradeable.

Our technology ingests the world's bio-data to predict clinical and market success. By synthesizing biology, chemistry, clinical data, IP landscapes, and team lineage, our AI models spot hidden signals and distill complexity into a tradeable rating, a standardized unit of risk.

Born at ETH Zürich and operating across San Francisco and Zürich, we are working toward a future where science is priced, rated, and traded with the efficiency of the global capital markets.

floatz

Org chart

Teams

Offices